Adjunctive pharmacotherapy in neonates with respiratory failure

Seminars in Fetal and Neonatal Medicine

Volumn 14, Issue 1, 2009, Pages 49-55

  Fok, Tai Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti inflammatory agents; Bronchodilators; Diuretics; Mucolytic agents; Newborns

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ATROPINE; AZITHROMYCIN; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARA CELL PROTEIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DIURETIC AGENT; DORNASE ALFA; FUROSEMIDE; HYPERTENSIVE FACTOR; IPRATROPIUM BROMIDE; ISOETARINE; ISOPRENALINE; MACROLIDE; MUCOLYTIC AGENT; ORCIPRENALINE; OXYGEN; PENTOXIFYLLINE; SALBUTAMOL; SODIUM; SPIRONOLACTONE; TERBUTALINE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; AEROSOL; AIRWAY RESISTANCE; ARTICLE; ATELECTASIS; BLOOD GAS; CEREBRAL PALSY; CHLORIDE DEPLETION; CHOLELITHIASIS; CYSTIC FIBROSIS; DEVELOPMENTAL DISORDER; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPERURICEMIA; HYPOCHLOREMIA; HYPONATREMIA; HYPOVOLEMIA; INFECTION; LUNG COMPLIANCE; LUNG DYSPLASIA; MECONIUM ASPIRATION; METABOLIC ALKALOSIS; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC EXAMINATION; OSTEOPENIA; OTOTOXICITY; OXYGEN THERAPY; PATENT DUCTUS ARTERIOSUS; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RETROLENTAL FIBROPLASIA; SIDE EFFECT; VOLUME DEPLETION;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; BRONCHOPULMONARY DYSPLASIA; DIURETICS; EXPECTORANTS; HUMANS; INFANT, NEWBORN; MECONIUM ASPIRATION SYNDROME; OXYGEN INHALATION THERAPY; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY;

EID: 57349191172     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2008.08.002     Document Type: Article

References (103)

1. Fok T.F., Lam K., Ng P.C., et al. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 12 (1998) 159-164
2. Fok T.F., Monkman S., Dolovich M., et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 21 (1996) 301-309
3. Grigg J., Arnon S., Jones T., Clarke A., and Silverman M. Delivery of therapeutic aerosols to intubated infants. Arch Dis Child 67 (1992) 25-30
4. Northway W.H., Rosan R.C., and Peter D.Y. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276 (1967) 357-368
5. Denjean A., Guimaraes H., Migdal M., Miramand J.L., Dehan M., and Gaultier C. Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants. J Pediatr 120 (1992) 974-979
6. Kraemer R., Birrer P., Modelska K., Aebischer C.C., and Schöni M.H. A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary dysplasia. Eur J Pediatr 151 (1992) 57-60
7. Kao L.C., Warburton D., Platzker A.C.G., and Keens T.G. Effect of isoproterenol inhalation on airway resistance in chronic bronchopulmonary dysplasia. Pediatrics 73 (1984) 509-514
8. Cabal L.A., Larrazabal C., Ramanathan R., et al. Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease. J Pediatr 110 (1987) 116-119
9. Motoyama E.K., Fort M.D., Klesh K.W., Mutich R.L., and Guthrie R.D. Early onset airway reactivity in premature infants with bronchopulmonary dysplasia. Am Rev Respir Dis 136 (1987) 50-57
10. Kao L.C., Durand D.J., and Nickerson B.G. Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. Pediatr Pulmonol 6 (1989) 74-80
11. Fok T.F., Lam K., Ng P.C., et al. Randomised crossover trial of salbutamol aerosol delivered by metered dose inhaler, jet nebuliser, and ultrasonic nebuliser in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 79 (1998) F100-F104
12. Wilkie R.A., and Bryan M.H. Effect of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr 111 (1987) 278-282
13. Rotschild A., Solimano A., Puterman M., Smyth J., Sharma A., and Albersheim S. Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. J Pediatr 115 (1989) 984-991
14. Yuksel B., Greenough A., and Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child 65 (1990) 782-785
15. Pfenninger J., and Aebi C. Respiratory response to salbutamol (albuterol) in ventilator- dependent infants with chronic lung disease: pressurized aerosol delivery versus intravenous injection. Intensive Care Med 19 (1993) 251-255
16. Lee H., Arnon S., and Silverman M. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. Arch Dis Child 70 (1994) F218-F222
17. Brundage K.L., Mohsini K.G., Froese A.B., and Fisher J.T. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis 142 (1990) 1137-1142
18. Denjean A., Paris-Llado J., Zupan V., et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr 157 (1998) 926-931
19. Ng G.Y., Da S., and Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 3 (2001) CD003214
20. Zimmerman J.J. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin Perinatol 22 (1995) 429-456
21. Bland R.D., McMillan D.D., and Bressack M.A. Decreased pulmonary transvascular fluid filtration in awake newborn lambs after intravenous furosemide. J Clin Invest 62 (1978) 601-609
22. Davis J.M., Sinkin R.A., and Aranda J.V. Drug therapy for bronchopulmonary dysplasia. Pediatr Pulmonol 8 (1990) 117-125
23. Green T.P., Thompson T.R., Johnson D.E., and Lock J.E. Furosemide promotes patent ductus arteriosus in premature infants with respiratory-distress syndrome. N Engl J Med 308 (1983) 743-748
24. Brion L.P., and Soll R.F. Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2 (2001) CD001454
25. Kao L.C., Warburton D., Sargent C.W., Platzker A.C.G., and Keens T.G. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr 103 (1983) 624-629
26. Engelhardt B., Elliott S., and Hazinski T.A. Short- and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia. J Pediatr 109 (1986) 1034-1039
27. Najak Z.D., Harris E.M., Lazzara Jr. A., and Pruitt A.W. Pulmonary effects of furosemide in preterm infants with lung disease. J Pediatr 102 (1983) 758-763
28. Patel H., Yeh T.F., Jain R., and Pildes R. Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia. Am J Dis Child 139 (1985) 917-919
29. Stefano J.L., and Bhutani V.K. Role of furosemide therapy after booster-packed erythrocyte transfusions in infants with bronchopulmonary dysplasia. J Pediatr 117 (1990) 965-968
30. Logvinoff M.M., Lemen R.J., Taussig L.M., and Lamont B.A. Bronchodilators and diuretics in children with bronchopulmonary dysplasia. Pediatr Pulmonol 1 (1985) 198-203
31. Rush M.G., Engelhardt B., Parker R.A., and Hazinski T.A. Double-blind, placebo-controlled trial of alternate-day furosemide in infants with chronin bronchopulmonary dysplasia. J Pediatr 117 (1990) 112-118
32. McCann E.M., Lewis K., Deming D.D., Donovan M.J., and Brady J.P. Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr 106 (1985) 957-962
33. Segar J.L., Robillard J.E., Johnson K.J., Bell E.F., and Chemtob S. Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. J Pediatr 120 (1992) 966-973
34. Brion L.P., and Primhak R.A. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 1 (2002) CD001453
35. Hufnagle K.G., Khan S.N., Penn D., Cacciarelli A., and Williams P. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 70 (1982) 360-363
36. Campfield T., Braden G., Flynn-Valone P., and Powell S. Effect of diuretics on urinary oxalate, calcium, and sodium excretion in very low birth weight infants. Pediatrics 99 (1997) 814-818
37. Brunette M.G., Mailloux J., and Lajeunesse D. Calcium transport through the luminal membrane of the distal tubule. I. Interrelationship with sodium. Kidney Int 41 (1992) 281-288
38. Kao L.C., Durand D.J., Philips B.L., and Nickerson B.G. Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia. J Pediatr 111 (1987) 439-444
39. Kao L.C., Warburton D., Cheng M.H., Cedeno C., Platzker A.C., and Keens T.G. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics 74 (1984) 37-44
40. Albersheim S.G., Solimano A.J., Sharma A.K., et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr 115 (1989) 615-620
41. Kao L.C., Durand D.J., McCrea R.C., Birch M., Powers R.J., and Nickerson B.G. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 124 5 Pt 1 (1994) 772-781
42. Brion L.P., Primhak R.A., and Mbrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 1 (2002) CD001817
43. Dikshit K., Vyden J.K., Forrester J.S., Chatterjee K., Prakash R., and Swan H.J. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 288 (1973) 1087-1090
44. Lavallee S.L., Iwamoto L.M., Claybaugh J.R., Dressel M.V., Sato A.K., and Nakamura K.T. Furosemide-induced airway relaxation in guinea pigs: relation to Na-K-2Cl cotransporter function. Am J Phys 273 1 Pt 1 (1997) L211-L216
45. Elwood W., Lotvall J.O., Barnes P.J., and Chung K.F. Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways. Am Rev Respir Dis 143 (1991) 1340-1344
46. Almirall J.J., Dolman C.S., and Eidelman D.H. Furosemide-induced bronchodilation in the rat bronchus: evidence of a role for prostaglandins. Lung 175 (1997) 155-163
47. Anderson S.D., He W., and Temple D.M. Inhibition by furosemide of inflammatory mediators from lung fragments. N Engl J Med 324 (1991) 131
48. Ohki Y., Nako Y., Koizumi T., and Morikawa A. The effect of aerosolised furosemide in infants with chronic lung disease. Acta Paediatr 86 (1997) 656-660
49. Rastogi A., Luayon M., Ajayi O.A., and Pildes R.S. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr 125 6 Pt 1 (1994) 976-979
50. Kugelman A., Durand M., and Garg M. Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics 99 (1997) 71-75
51. Prabhu V.G., Keszler M., and Dhanireddy R. Dose-dependent evaluation of the effects of nebulized furosemide on pulmonary function in ventilated preterm infants. J Perinatol 18 (1998) 357-360
52. Prabhu V.G., Keszler M., and Dhanireddy R. Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants. Arch Dis Child Fetal Neonatal Ed 77 (1997) F32-F35
53. Brion L.P., Primhak R.A., and Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 3 (2006) CD001694
54. Ahola T., Lapatto R., Raivio K.O., et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 143 (2003) 713-719
55. Sandberg K., Fellman V., Stigson L., Thiringer K., and Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 86 (2004) 275-279
56. Bibi H., Seifert B., Oullette M., and Belik J. Intratracheal N-acetylcysteine use in infants with chronic lung disease. Acta Paediatr 81 (1992) 335-339
57. Shak S., Capon D.J., Hellmiss R., Marsters S.A., and Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 87 (1990) 9188-9192
58. Erdeve O., Uras N., Atasay B., and Arsan S. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. Croat Med J 48 (2007) 234-239
59. El Hassan N.O., Chess P.R., Huysman M.W., Merkus P.J., and de Jongste J.C. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 108 (2001) 468-470
60. Ogletree M.L., Begley C.J., King G.A., and Brigham K.L. Influence of steroidal and nonsteroidal anti-inflammatory agents on the accumulation of arachidonic acid metabolites in plasma and lung lymph after endotoxemia in awake sheep. Measurements of prostacyclin and thromboxane metabolites and 12-HETE. Am Rev Respir Dis 133 (1986) 55-61
61. da Costa D.E., Nair A.K., Pai M.G., and Al Khusaiby S.M. Steroids in full term infants with respiratory failure and pulmonary hypertension due to meconium aspiration syndrome. Eur J Pediatr 160 (2001) 150-153
62. Salvia-Roiges M.D., Carbonell-Estrany X., Figueras-Aloy J., and Rodriguez-Miguelez J.M. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatr 93 (2004) 60-65
63. Tripathi S., Saili A., and Dutta R. Inflammatory markers in meconium induced lung injury in neonates and effect of steroids on their levels: a randomized controlled trial. Indian J Med Microbiol 25 (2007) 103-107
64. Tripathi S., and Saili A. The effect of steroids on the clinical course and outcome of neonates with meconium aspiration syndrome. J Trop Pediatr 53 (2007) 8-12
65. Ward M., and Sinn J. Steroid therapy for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 4 (2003) CD003485
66. Halliday H.L., and Ehrenkranz R.A. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 (2001) CD001146
67. Halliday H.L., and Ehrenkranz R.A. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2 (2000) CD001144
68. Halliday H.L., and Ehrenkranz R.A. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2 (2000) CD001145
69. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350 (2004) 1304-1313
70. American Academy of Pediatrics CoFaN. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002) 330-338
71. Dugas M.A., Nguyen D., Frenette L., et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 115 (2005) e566-e572
72. Inwald D.P., Trivedi K., Murch S.H., and Costeloe K. The effect of early inhaled budesonide on pulmonary inflammation in infants with respiratory distress syndrome. Eur J Pediatr 158 (1999) 815-816
73. Merz U., Kusenbach G., Hausler M., Peschgens T., and Hornchen H. Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Biol Neonate 75 (1999) 46-53
74. Jangaard K.A., Stinson D.A., Allen A.C., and Vincer M.J. Early prophylactic inhaled beclomethasone in infants less than 1250 g for the prevention of chronic lung disease. Paediatr Child Health 7 (2002) 13-19
75. Cloutier M.M. Nebulized steroid therapy in bronchopulmonary dysplasia. Pediatr Pulmonol 15 (1993) 111-116
76. Cole C.H., Colton T., Shah B.L., et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340 (1999) 1005-1010
77. Groneck P., Goetze-Speer B., and Speer C.P. Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Pediatr Pulmonol 27 (1999) 383-387
78. Gupta G.K., Cole C.H., Abbasi S., et al. Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 30 (2000) 275-281
79. Jonsson B., Eriksson M., Soder O., Broberger U., and Lagercrantz H. Budesonide delivered by dosimetric jet nebulization to preterm very low birthweight infants at high risk for development of chronic lung disease. Acta Paediatr 89 (2000) 1449-1455
80. Fok T.F., Lam K., Dolovich M., et al. Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 80 (1999) F203-F208
81. Pappagallo M., Abbasi S., and Bhutani V.K. Respiratory and systemic effects of inhaled dexamethasone on ventilator dependant preterm infants at risk for bronchopulmonary dysplasia. Indian J Pediatr 65 (1998) 273-282
82. Zimmerman J.J., Gabbert D., Shivpuri C., et al. Meter-dosed, inhaled beclomethasone attenuates bronchoalveolar oxyradical inflammation in premature infants at risk for bronchopulmonary dysplasia. Am J Perinatol 15 (1998) 567-576
83. Shah V., Ohlsson A., Halliday H.L., and Dunn M.S. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 4 (2007) CD001969
84. Halliday H.L., Patterson C.C., and Halahakoon C.W. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 107 (2001) 232-240
85. Shah S.S., Ohlsson A., Halliday H., and Shah V.S. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 1 (2003) CD002058
86. Aghai Z.H., Kode A., Saslow J.G., et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 62 (2007) 483-488
87. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 125 2 Suppl (2004) 41S-50S
88. Jobe A.H., and Ikegami M. Antenatal infection/inflammation and postnatal lung maturation and injury. Respir Res 2 (2001) 27-32
89. Ballard H.O., Anstead M.I., and Shook L.A. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 8 (2007) 41
90. Bruijnzeel P.L., Warringa R.A., Kok P.T., and Kreukniet J. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 99 (1990) 798-802
91. Kilpatrick L.E., Jakabovics E., McCawley L.J., Kane L.H., and Korchak H.M. Cromolyn inhibits assembly of the NADPH oxidase and superoxide anion generation by human neutrophils. J Immunol 154 (1995) 3429-3436
92. Viscardi R.M., Hasday J.D., Gumpper K.F., Taciak V., Campbell A.B., and Palmer T.W. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 156 (1997) 1523-1529
93. Watterberg K.L., and Murphy S. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. The Neonatal Cromolyn Study Group. Pediatrics 91 (1993) 803-806
94. Ng G.Y., and Ohlsson A. Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2 (2001) CD003059
95. Sullivan G.W., Carper H.T., Novick Jr. W.J., and Mandell G.L. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 56 (1988) 1722-1729
96. Raffin T.A. Acute lung injury and pentoxifylline. Crit Care Med 18 (1990) 1485-1486
97. Schermuly R.T., Roehl A., Weissmann N., et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1361-L1368
98. Lauterbach R., Szymura-Oleksiak J., Pawlik D., Warchol J., Lisowska-Miszczyk I., and Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med 19 (2006) 433-438
99. Peri A., Cordella-Miele E., Miele L., and Mukherjee A.B. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. J Clin Invest 92 (1993) 2099-2109
100. Vasanthakumar G., Manjunath R., Mukherjee A.B., Warabi H., and Schiffmann E. Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection. Biochem Pharmacol 37 (1988) 389-394
101. Wang S.Z., Rosenberger C.L., Bao Y.X., Stark J.M., and Harrod K.S. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 171 (2003) 1051-1060
102. Levine C.R., Gewolb I.H., Allen K., et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 58 (2005) 15-21
103. Greenough A., Pulikot A., and Dimitriou G. Prevention and management of meconium aspiration syndrome - assessment of evidence based practice. Eur J Pediatr 164 (2005) 329-330. *The most important references are indicated with an asterisks.